中华检验医学杂志
中華檢驗醫學雜誌
중화검험의학잡지
CHINESE JOURNAL OF LABORATORY MEDICINE
2008年
11期
1259-1263
,共5页
盛世乐%王青%覃文新%于彬%黄钢
盛世樂%王青%覃文新%于彬%黃鋼
성세악%왕청%담문신%우빈%황강
肺肿瘤%胞间信号肽类和蛋白质类%荧光免疫测定%肿瘤标记,生物学
肺腫瘤%胞間信號肽類和蛋白質類%熒光免疫測定%腫瘤標記,生物學
폐종류%포간신호태류화단백질류%형광면역측정%종류표기,생물학
Lung neoplasms%Intercellular signaling peptides and proteins%Fluoroimmunoassay%Tumor markers,biological
目的 建立Dickkopf-1(DKK-1)时间分辨免疫荧光分析(TR-IFMA)方法,并评价其在肺癌诊断和病理分期中的价值.方法 用双抗夹心原理建立DKK-1 TR-IFMA,并对其灵敏度、批内、批间差异和准确性等各项指标进行考核.同时用以测定212例肺癌、72例肺良性疾病患者和120名健康人血清DKK-1含量,以分析血清DKK-1水平与肺癌不同临床病理特性的相关性.结果 DKK-1TR-IFMA的稳定性好,线性宽,其检测灵敏度为0.08μg/L,批内和批间变异系数均<6.5%,与商业ELISA试剂盒相关性好(r=0.972,P=0.01).肺癌组血清DKK-1水平[31.93(79.47～18.03)μg/L]显著高于肺良性疾病组[15.25(18.41～11.49)μg/L]和正常对照组[13.90(16.91～11.02)μg/L],但DKK-1水平与年龄、性别、肺癌病理组织类型无关,与TNM分期(r=0.37,P<0.001)、有无淋巴结转移(r=0.52,P<0.001)和远处转移(r=0.62,P=0.001)显著相关;血清DKK-1诊断肺癌的总敏感度为68.4%,特异度为92.2%,准确性为82.1%,阳性预测值为90.6%,阴性预测值为72.5%;血清DKK-1诊断小细胞性肺癌的敏感度和准确性稍高于非小细胞性肺癌(70.7%vs 69.5%,85.6%vs 80.7%).结论 DKK-1可作为一项肺癌血清学标志,适用于肺癌的辅助诊断和病理分期.TR-IFMA检测血清DKK-1方法准确可靠,且为肺癌的DKK-1定量检测提供了技术平台.
目的 建立Dickkopf-1(DKK-1)時間分辨免疫熒光分析(TR-IFMA)方法,併評價其在肺癌診斷和病理分期中的價值.方法 用雙抗夾心原理建立DKK-1 TR-IFMA,併對其靈敏度、批內、批間差異和準確性等各項指標進行攷覈.同時用以測定212例肺癌、72例肺良性疾病患者和120名健康人血清DKK-1含量,以分析血清DKK-1水平與肺癌不同臨床病理特性的相關性.結果 DKK-1TR-IFMA的穩定性好,線性寬,其檢測靈敏度為0.08μg/L,批內和批間變異繫數均<6.5%,與商業ELISA試劑盒相關性好(r=0.972,P=0.01).肺癌組血清DKK-1水平[31.93(79.47～18.03)μg/L]顯著高于肺良性疾病組[15.25(18.41～11.49)μg/L]和正常對照組[13.90(16.91～11.02)μg/L],但DKK-1水平與年齡、性彆、肺癌病理組織類型無關,與TNM分期(r=0.37,P<0.001)、有無淋巴結轉移(r=0.52,P<0.001)和遠處轉移(r=0.62,P=0.001)顯著相關;血清DKK-1診斷肺癌的總敏感度為68.4%,特異度為92.2%,準確性為82.1%,暘性預測值為90.6%,陰性預測值為72.5%;血清DKK-1診斷小細胞性肺癌的敏感度和準確性稍高于非小細胞性肺癌(70.7%vs 69.5%,85.6%vs 80.7%).結論 DKK-1可作為一項肺癌血清學標誌,適用于肺癌的輔助診斷和病理分期.TR-IFMA檢測血清DKK-1方法準確可靠,且為肺癌的DKK-1定量檢測提供瞭技術平檯.
목적 건립Dickkopf-1(DKK-1)시간분변면역형광분석(TR-IFMA)방법,병평개기재폐암진단화병리분기중적개치.방법 용쌍항협심원리건립DKK-1 TR-IFMA,병대기령민도、비내、비간차이화준학성등각항지표진행고핵.동시용이측정212례폐암、72례폐량성질병환자화120명건강인혈청DKK-1함량,이분석혈청DKK-1수평여폐암불동림상병리특성적상관성.결과 DKK-1TR-IFMA적은정성호,선성관,기검측령민도위0.08μg/L,비내화비간변이계수균<6.5%,여상업ELISA시제합상관성호(r=0.972,P=0.01).폐암조혈청DKK-1수평[31.93(79.47～18.03)μg/L]현저고우폐량성질병조[15.25(18.41～11.49)μg/L]화정상대조조[13.90(16.91～11.02)μg/L],단DKK-1수평여년령、성별、폐암병리조직류형무관,여TNM분기(r=0.37,P<0.001)、유무림파결전이(r=0.52,P<0.001)화원처전이(r=0.62,P=0.001)현저상관;혈청DKK-1진단폐암적총민감도위68.4%,특이도위92.2%,준학성위82.1%,양성예측치위90.6%,음성예측치위72.5%;혈청DKK-1진단소세포성폐암적민감도화준학성초고우비소세포성폐암(70.7%vs 69.5%,85.6%vs 80.7%).결론 DKK-1가작위일항폐암혈청학표지,괄용우폐암적보조진단화병리분기.TR-IFMA검측혈청DKK-1방법준학가고,차위폐암적DKK-1정량검측제공료기술평태.
Objective To develop a highly sensitive and accurate time-resolved immunofluorometric assay (TR-IFMA) for measurement of Dickkopf-1(DKK-1),as a novel serologic biomarker for lung cancer. Methods The study constructed a two-manoclonal-antibody "sandwich"-type assay and the sensitivity, within run CV and between run CV and accuracy were evaluated. Serum DKK-1 concentrations were measured by TR-IFMA in 120 healthy controls, in 72 benign lung disease patients, and in 212 lung cancer patients before surgery. The association between serum DKK-1 levels and clinicopathological features were evaluated. Results A standard curve for DKK-1 TR-IFMA had been developed with good sensitivity (0.08 μg/L). Both within run CV and between run CV were less than 6.5%. Accuracy studies, parallelism and precision data were determined and all found to be satisfactory. The validity of DKK-1 assay was confirmed by the good correlation between the results obtained by TR-IFMA and commercial ELISA (r=0.972, P=0.01). The serum levels of DKK-1 were higher in lung cancer patients 31.93(79.47-18.03) μg/L than in benign lung diseases 15.25(18.41-11.49) μg/L and in healthy controls 13. 90( 16. 91-11.02) μg/L DKK-1 levels were significant associated with the presence of distant metastases, as well as lymph node metastases and TNM stage, but not with patients' age, gender and tumor histology. At the cutoff of 22.63 μg/L, the diagnostic sensitivity, specificity, accuracy, positive predictive value and negative predictive value of the TR-IFMA for lung carcinoma were 68.4%, 92.2%, 82.1% ,90.6% and 72.5%. Diagnostic sensitivity and accuracy were higher for small cell carcinoma than for non-small cell carcinoma (70.7% vs 69.5% and 85.6% vs 80.7%, respectively). Conclusions A highly sensitive and reliable TR-IFMA for DKK-1 has been developed. The determination of serum DKK-1 levels may be useful for diagnosis and tumor staging of lung cancer.
